The two companies have been working together since February and now are formalizing plans to develop and test new products.
WUSTL spinout PercayAI will provide augmented intelligence technology to Canopy Biosciences' RNA-seq and NanoString tests to inform drug discovery.
Hatched from the computational genomics lab at Ghent University, BioLizard offers a small but complementary team to tackle AI and molecular pipeline challenges.
The incubator, housed on the campus of the Karolinska Institute, draws upon the experience of its partners in genomics, diagnostics, business development, and corporate law.
Lantern will use its AI platforms and NCI's omics datasets to identify and validate predictive genomic signatures for drugs it is developing.
Startup BioLizard will develop the algorithm to help Novigenix migrate its immuno-transcriptiomic assay for early colorectal cancer detection to a new NGS-based platform.
Tempus is eligible for milestone payments and royalties for any oncology therapeutics Genmab might develop based on their joint research projects.
The San Francisco-based microbial genomics firm will sell off its product lines, testing labs, IP, and data within the next three months.
In an abstract to be presented at ASHG, Baylor Genetics researchers will discuss how Emedgene's AI-driven platform helped them streamline and standardize sequencing review.
The longtime quest of one Microsoft data scientist to stop infant crib deaths has grown into a genomics and AI research program with lofty goals.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.